Opioid Drug Abuse Testing Key Topic at Congress
|
By LabMedica International staff writers Posted on 08 Jun 2017 |
Development of new diagnostic procedures for opioid drugs and augmenting communication pathways between laboratory, clinician, and patient are important topics that will be addressed at the July 30 to August 3, 2017, AACC Annual Meeting & Clinical Lab Expo (San Diego, CA, USA).
In the United States - according to data reported in the December 2016 issue of the journal Morbidity and Mortality Weekly Report - opioids accounted for more than two-thirds of all drug overdose deaths in 2015, 15.6% more than the previous year, and drug overdose deaths nearly tripled between 1999 and 2014.
While official agencies and medical groups recommend clinical laboratory tests to support efforts aimed at curbing opioid drug abuse, many physicians may not be fully equipped with the knowledge required to interpret this test data for their patients. To help in this regard, nationally recognized centers, such as the Mayo Clinic (Rochester, MN, USA) have entered the limelight.
Physician requests for assistance in interpreting pain management tests at the Mayo Clinic increased after the [U.S.] Centers for Disease Control and Prevention (Atlanta, GA, USA) issued guidelines in March 2016 recommending urine drug testing before starting patients on opioid therapy and for monitoring them afterward. This guideline and others are driving the testing, but also leading to more confusion in terms of which type of laboratory tests to use - for example, immunoassays versus definitive methods - which specific tests to include, the frequency, and how to interpret those tests.
To help out, the Mayo Clinic now deploys many tools to help providers navigate the nuances of drug testing. Mayo’s online test catalog includes a primer on interpreting drug tests for compliance, along with short “hot topic” videos and other online educational tools.
Other institutions are also rising to the challenge. Vanderbilt University (Nashville, TN, USA) for example, now makes it possible for physicians to request interpretative services at the time they order a test.
In response to the opioid crisis, discussions at the AACC Annual Meeting will emphasize that clinical labs and their physician clients need to work together to stay abreast of drug testing needs in their local communities.
Related Links:
AACC Annual Meeting & Clinical Lab Expo
Mayo Clinic
Centers for Disease Control and Prevention
Vanderbilt University
In the United States - according to data reported in the December 2016 issue of the journal Morbidity and Mortality Weekly Report - opioids accounted for more than two-thirds of all drug overdose deaths in 2015, 15.6% more than the previous year, and drug overdose deaths nearly tripled between 1999 and 2014.
While official agencies and medical groups recommend clinical laboratory tests to support efforts aimed at curbing opioid drug abuse, many physicians may not be fully equipped with the knowledge required to interpret this test data for their patients. To help in this regard, nationally recognized centers, such as the Mayo Clinic (Rochester, MN, USA) have entered the limelight.
Physician requests for assistance in interpreting pain management tests at the Mayo Clinic increased after the [U.S.] Centers for Disease Control and Prevention (Atlanta, GA, USA) issued guidelines in March 2016 recommending urine drug testing before starting patients on opioid therapy and for monitoring them afterward. This guideline and others are driving the testing, but also leading to more confusion in terms of which type of laboratory tests to use - for example, immunoassays versus definitive methods - which specific tests to include, the frequency, and how to interpret those tests.
To help out, the Mayo Clinic now deploys many tools to help providers navigate the nuances of drug testing. Mayo’s online test catalog includes a primer on interpreting drug tests for compliance, along with short “hot topic” videos and other online educational tools.
Other institutions are also rising to the challenge. Vanderbilt University (Nashville, TN, USA) for example, now makes it possible for physicians to request interpretative services at the time they order a test.
In response to the opioid crisis, discussions at the AACC Annual Meeting will emphasize that clinical labs and their physician clients need to work together to stay abreast of drug testing needs in their local communities.
Related Links:
AACC Annual Meeting & Clinical Lab Expo
Mayo Clinic
Centers for Disease Control and Prevention
Vanderbilt University
Latest AACC 2017 News
- Siemens Healthineers Showcases Atellica Solution at AACC 2017
- Ortho Clinical Diagnostics Highlights Immunodiagnostics at Clinical Expo
- Combating Infectious Diseases Key Focus of AACC
- World's First Fully Integrated LC-MS/MS Clinical Analyzer Unveiled
- Clinical Chemistry Analyzer Provides DAU Screening
- Diatron Displays New Hematology Analyzer at UAE Congress
- Microscan Demonstrates Advanced Technology at Scientific Meeting
- AACC Middle East to Be Held in Abu Dhabi
- AACC 2017 Focus on CRISPR and Futuristic Testing Devices
- Keynote Address to Focus on CRISPR/Cas9 Gene Editing
- Winner of Qualcomm Tricorder XPrize Unveiled at AACC
- Annual Meeting Offers Industry Education and Entertainment
Channels
Clinical Chemistry
view channel
International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes
Type 1 diabetes (T1D) is an autoimmune disease that can develop in childhood or adulthood and affects an estimated 9.5 million people worldwide. Its complications range from acute diabetic ketoacidosis... Read more
Algorithm Uses Blood Biomarkers to Improve Alzheimer’s Trial Screening
Alzheimer’s disease is a progressive neurodegenerative disorder that causes memory loss and functional decline. Screening cognitively healthy adults for prevention trials is slow and costly because many... Read moreMolecular Diagnostics
view channel
Combined Blood and Genetic Tests Estimate Timing of Alzheimer’s Symptom Onset
Predicting when Alzheimer’s disease will manifest remains a major clinical challenge, particularly before cognitive decline is evident. Blood biomarkers and genetic risk markers can flag elevated risk,... Read more
Blood Protein Analysis Helps Interpret Uncertain Rare Disease Variants
Many patients with suspected rare genetic conditions remain undiagnosed even after genome or exome sequencing, leaving clinicians with limited evidence to interpret uncertain variants. Variants of uncertain... Read moreHematology
view channel
Hidden Molecular Mechanism Behind HIT Blood-Clotting Disorder Revealed
Immune-mediated thrombosis following heparin therapy can be sudden and severe, creating urgent diagnostic challenges. In heparin-induced thrombocytopenia (HIT), antibodies against platelet factor 4 (PF4)... Read more
Borderline Anemia May Carry Higher Risk Than Current Thresholds Suggest
Hemoglobin concentration is among the most frequently ordered blood tests in primary and hospital care. In older adults, both high and low values have been linked to adverse outcomes, including cognitive... Read moreImmunology
view channel
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read moreMicrobiology
view channel
Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
Hospitals face persistent pressure to improve diagnostic accuracy while reducing unnecessary testing and costs. Misordered or overused assays can complicate infection metrics, trigger penalties, and strain... Read more
Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read morePathology
view channel
AI Spatial Analysis of Routine Slides Helps Predict Pancreatic Cancer Recurrence
Predicting which patients with pancreatic cancer will recur after treatment and surgery remains challenging. Pathology evaluation typically measures residual tumor burden, but recent work found that tumor... Read more
Hybrid Computational Imaging Method Improves Digital Pathology Resolution
Digital pathology depends on high-resolution whole-slide imaging to capture diagnostically relevant cellular and tissue features, yet conventional methods often force trade-offs between speed, cost, and detail.... Read moreTechnology
view channel
Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read moreIndustry
view channel
Blood-Based Neurology Biomarker Assays Authorized for Use in Brazil
H.U. Group Holdings Inc. (Tokyo, Japan) and its wholly owned subsidiary Fujirebio announced that the Brazilian Health Regulatory Agency (ANVISA) has authorized the Lumipulse G NfL Blood and Lumipulse G... Read more








